Table 3.

Comparison of diagnostic performance for HCC between CEUS LI-RADS and other diagnostic criteria

Study	Study type	Contrast agent	LI-RADS		“APHE and washout”		On-site diagnosis†
			Sen (%)	Spe (%)	Sen (%)	Spe (%)	Sen (%)	Spe (%)
Huang et al. [17],* (2020)	Retrospective	SonoVue	73.3	97.1	88.6	87.1	N/A	N/A
Strobel et al. [19] (2021)	Prospective	Unmentioned	65.2	78.6	74.3	63.0	91.5	67.4
Schellhaas et al. [20] (2021)	Prospective	Unmentioned	64.0	78.9	68.6	57.9	90.9	64.9
Zhou et al. [18] (2022)	Prospective	SonoVue	38.6–63.6	92.7–100.0	88.6–100.0	28.6–64.3	N/A	N/A

HCC, hepatocellular carcinoma; CEUS, contrast-enhanced ultrasound; LI-RADS, Liver Imaging Reporting and Data System; APHE, arterial phase hyperenhancement; Sen, sensitivity; Spe, specificity; N/A, not applicable.

^*All lesions are 20 mm or smaller.

^†Subjective on-site diagnosis of the examiner.